STOCK TITAN

Accuray Incorp - ARAY STOCK NEWS

Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.

Company Overview

Accuray Incorp (NASDAQ: ARAY) is a pioneering radiation oncology company dedicated to developing, manufacturing, and supporting innovative treatment solutions. With its robust portfolio of advanced radiotherapy systems, Accuray stands out in the field of robotic radiosurgery and precision radiation treatment. Technologies such as CyberKnife and Radixact integrate real-time tracking, advanced imaging, and dynamic treatment planning to deliver sub-millimetre accuracy when treating tumors. This unique blend of robotics and radiation therapy is essential for accurate, effective, and efficient cancer treatment.

Core Technologies and Capabilities

Accuray’s solutions are designed to meet the complex needs of modern oncology. The company’s systems automatically track and adjust to patient and tumor motion, ensuring delivery of high doses of radiation with exceptional precision. Key technologies include:

  • Real-Time Motion Tracking: Automated tracking systems that detect and correct patient movements during treatment.
  • Advanced Imaging Integration: Solutions like ClearRT provide diagnostic-quality imaging to guide therapy, ensuring optimal patient positioning and treatment accuracy.
  • Adaptive Treatment Planning: Innovative planning systems such as the Accuray Precision TPS allow clinicians to adapt treatment plans in real-time, accounting for changes in tumor characteristics and patient anatomy.
  • Robotic Radiosurgery: The CyberKnife System is a testament to the integration of robotics with medical imaging, delivering ultra-hypofractionated treatments in just a few outpatient sessions.

Market Position and Business Model

Accuray operates in a competitive global market characterized by rapid technological advances and high clinical demands. The company’s business model is built around the development and commercialization of cutting-edge devices that support a complete continuum of care—from pre-treatment planning to post-treatment care. By partnering with hospitals, cancer centers, and clinicians, Accuray not only provides state-of-the-art equipment but also offers training and support services, enhancing operational efficiencies in radiation oncology departments.

Innovation and Industry Influence

Innovation is at the heart of Accuray’s operations. The constantly evolving product portfolio, which includes enhancements in imaging, treatment planning, and adaptive delivery technologies, has positioned the company as a critical player in improving patient access to high-precision radiotherapy. These innovations have garnered recognition across global markets, particularly in regions with growing demand for advanced cancer care solutions.

Clinical Impact and Patient Care

The primary goal of Accuray’s technologies is to help patients live longer and better lives by offering treatments that are both effective and minimally disruptive. The advanced radiation therapy systems are designed to reduce treatment times, lower the risk of side effects, and deliver high-quality, personalized care. Clinicians benefit from enhanced workflow efficiencies and the ability to treat a diverse range of cancers—from common malignancies to complex cases that require sophisticated robotic surgery.

Operational Excellence and Global Reach

Headquartered in the United States with a worldwide network of facilities, Accuray has established a robust presence in both developed and emerging markets. The company’s strategic partnerships and joint ventures allow it to tailor its products to local market needs, ensuring that precise radiation therapies are available where they are needed most. This global footprint, combined with continuous investment in research and development, makes Accuray a respected name in radiation oncology.

Conclusion

Through its commitment to technical excellence and innovation, Accuray Incorp delivers comprehensive radiotherapy treatment solutions that set the standard of care in radiation oncology. The company’s integrated approach—leveraging advanced technologies to meet complex clinical challenges—has redefined the possibilities in tumor treatment. Investors and industry analysts recognize Accuray not only for its state-of-the-art products but also for its sustainable business model and its pivotal role in enhancing global patient care in radiation therapy.

Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) announced a collaboration with Brainlab to enhance the CyberKnife treatment platform for neuro-radiosurgery. This partnership will integrate Brainlab's Elements planning software, improving contouring capabilities for neurosurgeons. Additionally, interoperability with Brainlab's Snke OS will streamline patient data management and optimize treatment workflows. The CyberKnife S7 System utilizes advanced robotic technology for precise radiation therapy targeting tumors while preserving healthy tissue. The collaboration aims to elevate the standard of care in neurosurgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
none
-
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) has appointed Mike Leischer as vice president and general manager of the Americas region, effective immediately. Leischer brings over 23 years of experience in sales and strategy from companies like Canon Medical Systems USA and GE Healthcare. His role will involve leading commercial teams and driving business strategy to meet the company's objectives. Leadership expressed confidence in his ability to enhance market share and build strategic partnerships, stating this is a pivotal time for Accuray due to its product portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
management
-
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) will report its financial results for the first quarter of fiscal year 2021, ending September 30, 2020. The announcement will be made after the market closes on October 29, 2020. Management will conduct a conference call at 1:30 p.m. PT on the same day to discuss the results. Dial-in details are provided for both domestic and international participants. A live webcast will also be available on the company’s Investor Relations website, with a replay accessible until the next quarterly results are announced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
conferences earnings
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) will host an Analyst & Investor Meeting on October 26, 2020, in conjunction with the ASTRO Annual Meeting. The virtual event will run from 1:00 pm ET to 3:00 pm ET. Management will discuss the company's growth strategies focused on advancing radiation therapy, featuring insights from physician guest speakers. Registration is required by October 20, 2020, and a replay will be available post-event on Accuray's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
conferences
-
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) has announced that several leading hospitals in Japan are now utilizing its Radixact® System combined with Synchrony® Automatic, Real-time Motion Synchronization Technology for advanced cancer treatments. This technology allows more precise treatment of tumors that move, reducing radiation exposure to healthy tissue. Notably, Takarazuka City Hospital treated the first Synchrony patient in Asia and was the first globally to perform a liver treatment with this technology. The adoption of these systems in Japan, which has the highest penetration of such innovations, aims to enhance cancer care and treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
none
-
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) will present at the Lake Street Capital Markets Best Ideas Growth (BIG4) Conference on September 17, 2020. CEO Joshua H. Levine and CFO Shig Hamamatsu are set to share insights with institutional investors during this virtual event. Prior to the conference, management will engage in various one-on-one and group discussions throughout the day. For more information, visit Lake Street Capital Markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
conferences
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) has announced a significant milestone with the University Hospital Città della Salute e della Scienza in Turin, Italy, successfully treating the first cancer patients in the EIMEA region using the Radixact® System featuring Synchrony® technology. This innovative approach allows for personalized cancer care by adapting treatment based on real-time patient movements, enhancing the precision of radiation therapy. The first patient treated was an 85-year-old man with early-stage lung cancer, benefiting from the system's ability to minimize harm to healthy tissues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
-
Rhea-AI Summary

Accuray reported its Q4 and fiscal year 2020 results, highlighting gross orders of $94.3 million and a net revenue of $95.0 million. The company experienced a net loss of $0.8 million for Q4, while fiscal year net income reached $3.2 million. Notably, gross product orders increased by 10% to $377.3 million year-over-year, with an ending backlog of $602.7 million, up 22%. However, the company refrained from providing guidance for fiscal 2021 due to uncertainties surrounding COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.9%
Tags
-
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) announced the appointment of Anne B. Le Grand to its Board of Directors, effective July 16, 2020. Ms. Le Grand brings over 25 years of experience in the healthcare technology sector, previously serving at IBM Watson Health Imaging and Philips Health Systems. Her role aims to enhance Accuray's product innovation in radiation therapy. CEO Joshua H. Levine highlighted her track record in launching market-driven products vital for financial growth. This strategic addition to the board reflects Accuray's commitment to improving cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
management
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) will announce its financial results for Q4 and fiscal year 2020, ending June 30, on August 13, 2020. The announcement will take place after market close, followed by a conference call at 1:30 p.m. PT/4:30 p.m. ET. Investors can access a live webcast and a replay on the company’s website. Accuray develops advanced radiotherapy systems aimed at improving cancer treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences earnings

FAQ

What is the current stock price of Accuray Incorp (ARAY)?

The current stock price of Accuray Incorp (ARAY) is $1.82 as of April 2, 2025.

What is the market cap of Accuray Incorp (ARAY)?

The market cap of Accuray Incorp (ARAY) is approximately 183.0M.

What does Accuray Incorp specialize in?

Accuray focuses on developing, manufacturing, and supporting advanced radiation therapy systems for oncology, including robotic radiosurgery solutions.

What are some key technologies developed by Accuray?

Key technologies include the CyberKnife System, Radixact platforms, ClearRT imaging solutions, Synchrony real-time tracking, and adaptive treatment planning systems.

How do Accuray's systems improve cancer treatment?

Their systems deliver high doses of radiation with sub-millimetre accuracy, continuously tracking patient and tumor movements to ensure precise targeting and reduce treatment side effects.

Who are the primary customers of Accuray?

Primary customers include hospitals, cancer centers, and oncology clinics worldwide that require advanced radiotherapy solutions for effective patient care.

How does Accuray maintain its position in a competitive market?

Accuray invests heavily in R&D, forging strategic partnerships and joint ventures in emerging markets, and continuously innovates its product portfolio to meet evolving clinical needs.

What benefits does real-time tracking technology offer?

Real-time tracking technology automatically adjusts for patient and tumor movement, enhancing treatment precision and allowing clinicians to deliver effective radiation therapy with reduced risk to healthy tissues.

How is Accuray contributing to global cancer care?

By providing advanced, market-changing solutions that simplify complex treatments and expand patient access to precision radiotherapy, Accuray significantly enhances clinical outcomes worldwide.
Accuray Incorp

Nasdaq:ARAY

ARAY Rankings

ARAY Stock Data

183.04M
100.18M
2.53%
60.86%
4.18%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MADISON